TNFRSF6B (TNF Receptor Superfamily Member 6B), also known as DcR3 (Decoy Receptor 3), is a soluble protein belonging to the tumor necrosis factor receptor superfamily. Unlike most receptors in this family, TNFRSF6B lacks a transmembrane domain, functioning primarily as a decoy receptor. It binds to and neutralizes ligands such as FasL, LIGHT, and TL1A, thereby modulating immune responses by inhibiting apoptosis, inflammatory signaling, and immune cell activation. This regulatory role links TNFRSF6B to pathologies like cancer, autoimmune diseases, and chronic inflammation, where its overexpression is often observed.
Antibodies targeting TNFRSF6B are critical tools for studying its expression, interaction networks, and pathophysiological roles. They are widely used in techniques like ELISA, Western blotting, immunohistochemistry, and flow cytometry to quantify protein levels or visualize tissue distribution. Neutralizing antibodies that block ligand-receptor interactions are particularly valuable for dissecting signaling pathways or exploring therapeutic strategies. In cancer research, TNFRSF6B antibodies may help uncover mechanisms of immune evasion or evaluate its prognostic significance. Additionally, these antibodies hold translational potential, serving as prototypes for biologics aimed at restoring immune homeostasis in diseases driven by dysregulated TNF signaling. Their development underscores the importance of TNFRSF6B as both a biomarker and a therapeutic target.